
- Volume 0 0
FIRMS PROTEST CANADIAN PATENT RULES
Generic drug companies in Canada are protesting controversialnew patent rules that they say will give brandeddrug makers in their country an unnecessarily longperiod of market exclusivity. Under rules issued to implementthe new legislation, brand-name drug companiesare provided with an 8-year ban on generic competition,regardless of whether there are relevant patents on theirproducts. According to generic leaders, if this 8-year banhad been in force during the past 5 years, it would haveadded $600 million to the country's prescription drugcosts and denied Canadians access to generic versionsof many blockbuster drugs.
Articles in this issue
almost 20 years ago
Preventing Rasagiline Drug Interactionsalmost 20 years ago
nacds SPEAKS OUT: Specialty Pharmaceuticals on the Risealmost 20 years ago
Strategies for Coping with Alzheimer's Diseasealmost 20 years ago
Captive at the Counter: When Robbers Take Hostages—Part 1almost 20 years ago
A Third Category? Medicines Go Behind the Counteralmost 20 years ago
Avoiding Common Dispensing Errorsalmost 20 years ago
Pharm School Receives Grant to Help with Part Dalmost 20 years ago
compounding HOTLINEalmost 20 years ago
The Pharmacist's Role in the Management of Alzheimer's Diseasealmost 20 years ago
A Challenging Path to a PharmD DegreeRelated to this article








